EMA · European Union
phentermine — EMA regulatory status
phentermine (QSIVA) regulatory status in the European Union is tracked from public EMA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: EMA refused.
Status snapshot
- Status
- EMA refused
- Brand
- QSIVA
- Mechanism
- Norepinephrine transporter releasing agent
- Target
- Sodium-dependent noradrenaline transporter
- Structured fields
- 6
Pharmacology context used for competitive intelligence: Norepinephrine transporter releasing agent. Target: Sodium-dependent noradrenaline transporter. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — EMA: refused.
Linked evidence on this spoke: 1 published clinical program and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| EMA | European Union | refused | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Phentermine | Unknown | Takeda | NCT01616082 |
Related hubs
FAQ
What is the EMA approval status of phentermine?
phentermine currently shows EMA refused in our European Union regulatory index. Confirm on the official EMA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get phentermine regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to phentermine?
This spoke lists 1 published program associated with phentermine in our pipeline index.